Davis Matthew W. has filed 4 insider transactions across 1 company since November 2025.
Most recent transaction: a grant/award of 50000 shares of Aquestive Therapeutics, Inc. ($AQST) on March 09, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Aquestive Therapeutics, Inc. | $AQST | Davis Matthew W. | Chief Development Officer | A | Common Stock | 50000 | $0.00 | 100,000.0000 | 122,003,113 | 100.00% | 0.04% |
| March 9, 2026 | Aquestive Therapeutics, Inc. | $AQST | Davis Matthew W. | Chief Development Officer | A | Non-Qualified Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| Nov. 10, 2025 | Aquestive Therapeutics, Inc. | $AQST | Davis Matthew W. | Chief Development Officer | A | Common Stock | 50000 | $0.00 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| Nov. 10, 2025 | Aquestive Therapeutics, Inc. | $AQST | Davis Matthew W. | Chief Development Officer | A | Non-Qualified Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |